This page shows what was measured, who it was measured in, and what that does not settle.
What Rosuvastatin does in the body
Rosuvastatin blocks the enzyme your liver uses to build cholesterol.
The liver responds by putting out more collection receptors that pull LDL particles from the blood. It is more water-loving than most statins, so it depends heavily on a liver transporter to get into the cell, and it is barely metabolised — which is why its interaction profile differs from atorvastatin's.
Why people take it. Used to lower cholesterol and prevent heart attacks or strokes.
What happened in people
In people without known heart disease, rosuvastatin reduced heart-related problems enough that one study stopped early.
✓ Reviewed first-read answer
Where this came from
A person wrote this and a reviewer approved it against this exact record. It carries no effect size.
A reviewer approved this against this record. The reviewed-claim record carrying the exact population and effect size does not exist yet.
No source is stored against this line.
The limit that matters most
It lowered both cholesterol and inflammation, so the study cannot show which change caused the benefit.
Where it acts
Hepatocyte endoplasmic reticulum (liver)
Kind of result
The kind of result is not recorded
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
Where each sentence above came from
A person wrote this explanation into the record, with the studies named in the path below.
A reviewer approved this sentence against this exact record and its sources.
The limit a reviewer approved as the one that matters most here.
The four opening statements run to 86 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Randomisation
Randomisation means chance decides who gets which treatment.
A picture of it, and where the picture fails
It is like a coin toss deciding the groups.
Where that stops being true. A coin toss is fair once. Fairness here comes from doing it for everyone.
What people get wrong. It is thought to make groups identical. It makes them similar on average, including on things nobody measured.
Allocation of participants to arms by a chance process, so that unmeasured factors are balanced in expectation.
Confidence interval
A confidence interval is the range the true answer is likely to sit in.
A picture of it, and where the picture fails
It is like a weather forecast giving a range rather than one number.
Where that stops being true. A forecast range covers tomorrow. This one covers what the study could resolve.
What people get wrong. The middle number is read as the answer. A range crossing zero means no change is still possible.
An interval estimate that would contain the true parameter in a stated proportion of repeated studies.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Cholesterol
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved15 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Blood sugar
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved2 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Healthy ageing
…Waiting for a reviewer1 registered study measure of this kind. No reviewed result yet.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Cholesterol
ldl c from baseline to week 12; reduction of ldl c following 12 weeks of treatment; low density lipoprotein cholesterol; fasting plasma low density lipoprotein cholesterol; triglycerides from baseline to final visit; reduction in ldl c after 6 weeks; achieving a target of fasting ldl c of 2mmol/ at study end; low density lipoprotein cholesterol level after 8 weeks
Blood sugar
urinary protein/creatinine in type 1 or 2 diabetes; glucose tolerance assessed by hba1c and fasting glucose
Healthy ageing
all cause mortality
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
△ Only a number moved
15 registered test measure.
— Not recorded
Harms were not a registered measure for this goal.
… Waiting for a reviewer
Who was studied is listed further down the page.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Composite of myocardial infarction, stroke, arterial revascularisation, hospitalisation for unstable angina or cardiovascular death
✓ The study showed what it set out to show
Who was studied
JUPITER (NCT00239681)
How many people
17802
Study design
Randomised double-blind placebo-controlled trial, stopped early, median 1.9 years
Compared against
A dummy treatment
Kind of result
Living longer, or avoiding a major event
What was found
HR 0.56 (95% CI 0.46-0.69), P < 0.00001
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. A higher incidence of physician-reported diabetes. The trial was stopped at a median 1.9 years, which inflates measured effect size and gives no long-term safety data.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablet, four strengths
Interval reported. 95% CI 0
Written into the record, not signed off as a reviewed claim.
Co-primary composites of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, with and without revascularisation, heart failure and resuscitated arrest
✓ The study showed what it set out to show
Who was studied
HOPE-3 (NCT00468923)
How many people
12705
Study design
Randomised double-blind placebo-controlled 2-by-2 factorial trial, median 5.6 years
Compared against
A dummy treatment
Kind of result
Living longer, or avoiding a major event
What was found
HR 0.76 (95% CI 0.64-0.91), P = 0.002 for the first co-primary outcome
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. Excess cataract surgery (3.8% against 3.1%, p=0.02) and excess muscle symptoms (5.8% against 4.7%, p=0.005).
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablet, four strengths
Interval reported. 95% CI 0
Written into the record, not signed off as a reviewed claim.
RNAWiki holds 5 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.1 registered measure of this kind. 3 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.19 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it changes in the body◇Read from sources, not yet reviewed
The path through the body
From what a person takes to what changes. A solid line is a step measured in people. A dashed line is a step nobody has measured that way.
Where a source records it acting
Liver: Accelerates expression of LDL-receptors and uptake of LDL-C from blood to the liver; sustained inhibition of cholesterol synthesis in the liver
US prescribing information · 02797697-300a-43db-92cf-9b78f08626be · read 2026-08-27
Blood and vessels: Leads to a decrease in plasma LDL-C and total cholesterol
US prescribing information · 02797697-300a-43db-92cf-9b78f08626be · read 2026-08-27
Start
Rosuvastatin
What a person takes: Oral tablet, four strengths.
The measurement behind this step
Once daily at any time of day, with or without food. Absorption is limited and the drug is barely metabolised, so its interactions are transporter interactions rather than cytochrome interactions — which is why it is often chosen where CYP3A4 inhibitors are in the picture.
Getting in
Poorly absorbed, barely metabolised, and mostly excreted unchanged
Only about a fifth of the tablet reaches the bloodstream, and the body hardly modifies what does. Most of it leaves in the faeces as the same molecule that went in.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Absolute bioavailability is roughly 20%. Metabolism is limited, with only minor CYP2C9 involvement and no meaningful CYP3A4 pathway, so the CYP3A4 interactions that dominate atorvastatin and simvastatin do not apply. About 90% of the dose is excreted unchanged in faeces. Systemic exposure is materially higher in East Asian populations, which the label addresses explicitly.
The molecule is unusually water-loving for a statin, so it does not slip through membranes. It relies almost entirely on a specific pump in liver cells, which is what keeps it concentrated in the liver.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Hepatic uptake is mediated principally by OATP1B1 (SLCO1B1), with OATP1B3 and NTCP contributing; efflux involves BCRP (ABCG2). The hydrophilicity conferred by the methanesulfonamide group limits passive entry into skeletal muscle and other non-hepatic tissue. Reduced-function SLCO1B1 and ABCG2 variants raise systemic exposure and are the transporter genetics behind both efficacy variation and myopathy risk.
The dihydroxy arm occupies the enzyme's substrate slot
The business end of the molecule imitates the natural raw material closely enough to sit in its place, and the rest of the molecule fills the space next to it so nothing else fits.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
The (3R,5S)-dihydroxyheptenoic acid arm mimics the HMG moiety of HMG-CoA in the reductase active site; the fluorophenyl-pyrimidine core occupies the adjacent hydrophobic groove. Rosuvastatin makes additional polar contacts through its methanesulfonamide that other statins do not, which is the structural basis of its higher potency per milligram.
The liver builds more LDL receptors and clears more particles
Short of cholesterol, the cell switches on the gene for the LDL catcher and puts more of them on its surface. Blood LDL falls because more is being taken out of circulation.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Falling intracellular sterol activates SREBP-2 through SCAP and the site-1 and site-2 proteases, raising LDLR transcription and surface receptor density. The same programme raises PCSK9, which degrades the receptor and limits the effect — the counter-regulatory step that PCSK9 antibodies remove. Hepatocyte C-reactive protein production also falls, by a route that is not the LDL receptor pathway.
LDL falls up to 50%, and events fall where events were atherosclerotic
The blood number drops within weeks and by more than most statins achieve. Whether that translates into fewer events depends entirely on whether the person's risk came from artery plaque in the first place.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
In JUPITER a 50% LDL reduction produced a hazard ratio of 0.56 in people whose risk was atherosclerotic. In AURORA a 43% LDL reduction in haemodialysis produced a hazard ratio of 0.96, and in GISSI-HF the hazard ratio for death was 1.00. The mechanism was engaged in all three; only in the first did engaging it change outcomes.
No suggested links are held for this record, so nothing is hidden from this path.
What we know
The record describes 5 steps from taking it to an effect in a person.
How we know it
Each step names the study behind it in the technical detail beside it.
What this does not prove
A change inside the body is a reason to look. It is not a result in a person.
Why it matters
A reader can see exactly where the chain stops being measured in people.
What we still do not know
No reviewed claim binds any of these steps to a named population.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
ldl c from baseline to week 12
reduction of ldl c following 12 weeks of treatment
low density lipoprotein cholesterol
fasting plasma low density lipoprotein cholesterol
urinary protein/creatinine in type 1 or 2 diabetes
urinary protein/creatinine at week 52
triglycerides from baseline to final visit
reduction in ldl c after 6 weeks
achieving a target of fasting ldl c of 2mmol/ at study end
low density lipoprotein cholesterol level after 8 weeks
and 9 more.
Meaningful
Things that change how a life goes, not only a number.
all cause mortality
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
general cardiovascular risk profile framingham heart study
flicker induced vasodilatation
flow mediated dilatation of the brachial artery
myocardial enzymes arise
height
cimt
carotid imt
infarct size
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. approximately 19 hours hours
Read from the label, which states: “The elimination half-life of rosuvastatin is approximately 19 hours.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Widely used where a large LDL reduction is wanted, including familial hypercholesterolaemia and statin-treated patients who have not reached target on another agent. On the WHO Model List of Essential Medicines.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca’s CRESTOR (rosuvastatin calcium) tablets.”
US prescribing information · 3066f572-e3db-4bf8-b9ee-bd32d9ed8c13 · read 2026-08-30
On older people, the label states: “Of the 10,275 patients in clinical studies with rosuvastatin, 3159 (31%) were 65 years and older, and 698 (6.8%) were 75 years and older.”
US prescribing information · 3066f572-e3db-4bf8-b9ee-bd32d9ed8c13 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Rosuvastatin is contraindicated for use in pregnant women since safety in pregnant women has not been established and there is no apparent benefit to therapy with rosuvastatin during pregnancy.”
US prescribing information · 3066f572-e3db-4bf8-b9ee-bd32d9ed8c13 · read 2026-08-30
On people who are breastfeeding, the label states: “8.3 Females and Males of Reproductive Potential Contraception Rosuvastatin may cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ].”
US prescribing information · 3066f572-e3db-4bf8-b9ee-bd32d9ed8c13 · read 2026-08-30
On people with reduced liver function, the label states: “Rosuvastatin is contraindicated in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels.”
US prescribing information · 3066f572-e3db-4bf8-b9ee-bd32d9ed8c13 · read 2026-08-30
On people with reduced kidney function, the label states: “Rosuvastatin exposure is not influenced by mild to moderate renal impairment (CLcr ≥ 30 mL/min/1.73 m 2 ).”
US prescribing information · 3066f572-e3db-4bf8-b9ee-bd32d9ed8c13 · read 2026-08-30
Where the result stopped carrying
CORONA: 5,011 patients with ischaemic systolic heart failure, LDL down 45%, primary endpoint hazard ratio 0.92 (p=0.12)
GISSI-HF: 4,574 patients with heart failure of any cause, hazard ratio for death of exactly 1.00 (p=0.943)
AURORA: 2,776 patients on haemodialysis, LDL down 43%, primary endpoint hazard ratio 0.96 (p=0.59)
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral tablet, four strengths
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
Once daily at any time of day, with or without food.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold. The rest of the recorded wording: Absorption is limited and the drug is barely metabolised, so its interactions are transporter interactions rather than cytochrome interactions — which is why it is often chosen where CYP3A4 inhibitors are in the picture.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take◇Read from sources, not yet reviewed
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
·Worth asking a clinician aboutWritten into the record from the studies named on this page
Muscle symptoms occurred in 5.8% against 4.7% on placebo in HOPE-3 (p=0.005) and rhabdomyolysis is rare. HOPE-3 also found an excess of cataract surgery (3.8% against 3.1%, p=0.02). JUPITER reported a higher incidence of physician-reported diabetes. Systemic exposure is roughly doubled in people of East Asian ancestry, which the label addresses. Interactions run through OATP1B1 and BCRP — ciclosporin, gemfibrozil and some antiretrovirals — rather than through CYP3A4.
Nobody counted how many people took this and were fine, so this cannot be turned into a rate.
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Rosuvastatin appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 27595 reaction mentions were counted. One report can name several reactions.
liver function test abnormal — 997 reaction mentions
myositis — 734 reaction mentions
immune-mediated myositis — 474 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral tablet, four strengths
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
A recorded note compares this form with the others that are sold. It is kept below, word for word.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
The recorded note, unchanged: Absorption is limited and the drug is barely metabolised, so its interactions are transporter interactions rather than cytochrome interactions — which is why it is often chosen where CYP3A4 inhibitors are in the picture.
No source is stored against this line.
What is recorded as being sold
317 products list this as an active ingredient in the United States drug directory. 317 of them contain it and nothing else.
FDA National Drug Code directory · 71610-187 · read 2026-08-29
They are sold as powder, tablet, tablet, coated and tablet, film coated, taken oral.
FDA National Drug Code directory · 71610-187 · read 2026-08-29
The regulator's established pharmacologic class for it is hmg-coa reductase inhibitor [epc] and hydroxymethylglutaryl-coa reductase inhibitors [moa].
FDA National Drug Code directory · 71610-187 · read 2026-08-29
169 published labels name it as an active ingredient. 169 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 3066f572-e3db-4bf8-b9ee-bd32d9ed8c13 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 3066f572-e3db-4bf8-b9ee-bd32d9ed8c13 · read 2026-08-29
Rosuvastatin Calcium is film-coated tablets at 5 mg, 10 mg, 20 mg, and 40 mg of rosuvastatin, recorded as prescription product; fda label in effect 2025-11-26 in the United States.
US prescribing information · 02797697-300a-43db-92cf-9b78f08626be · read 2026-08-27
Recorded price in US: 0.0333–0.0686 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 173 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.
Questions worth asking
Which of the trials of Rosuvastatin studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
Claims that go past the evidence
Things said about this substance that sound reasonable, and the exact step that is missing between the evidence and the claim.
✗Goes past the evidence
That JUPITER demonstrates a benefit of lowering inflammation independent of lowering LDL — both fell together in every participant
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That statin benefit generalises to populations with high cardiovascular mortality regardless of its cause — CORONA, GISSI-HF and AURORA say otherwise
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That the 44% relative reduction in JUPITER represents the long-run benefit — the trial ran a median 1.9 years and was stopped early
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That rosuvastatin is interchangeable with atorvastatin on outcomes — no head-to-head event trial has been run
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Rosuvastatin are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Every line above can be traced to the study named beside it. Follow the link and read it.
JUPITER: a 44% relative reduction in 17,802 people with normal cholesterol
In plain words
People with unremarkable cholesterol but a raised inflammation marker were given rosuvastatin or placebo. The trial was stopped after less than two years because the treated group had far fewer cardiovascular events.
What was measured
Composite of myocardial infarction, stroke, revascularisation, unstable angina and cardiovascular death over a median 1.9 years
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
JUPITER randomised 17,802 apparently healthy men and women with LDL cholesterol below 130 mg/dL and high-sensitivity C-reactive protein of 2.0 mg/L or higher to rosuvastatin 20 mg daily or placebo. The trial was stopped after a median 1.9 years. Rosuvastatin reduced LDL by 50% and high-sensitivity C-reactive protein by 37%. The primary composite of myocardial infarction, stroke, arterial revascularisation, hospitalisation for unstable angina or cardiovascular death occurred at 0.77 against 1.36 per 100 person-years: hazard ratio 0.56 (95% CI 0.46 to 0.69), p<0.00001. Myocardial infarction 0.46 (0.30 to 0.70), stroke 0.52 (0.34 to 0.79), death from any cause 0.80 (0.67 to 0.97), p=0.02. There was no significant increase in myopathy or cancer, but a higher incidence of physician-reported diabetes.
Written into the record, not signed off as a reviewed claim
JUPITER does not separate the LDL effect from the C-reactive protein effect
In plain words
The trial is quoted as proof that lowering inflammation prevents heart attacks. It lowered both cholesterol and the inflammation marker at once, in the same people, and no arm of the trial separated them.
What was measured
That JUPITER demonstrates a benefit from lowering inflammation as distinct from lowering LDL — the two fell together in every participant and no design element separated them
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Rosuvastatin lowered LDL by 50% and high-sensitivity C-reactive protein by 37% in the same participants; there was no arm in which one moved without the other. A 50% LDL reduction from a baseline under 130 mg/dL is on its own sufficient to explain a large part of the event reduction under the dose-response relationship the Cholesterol Treatment Trialists established across 26 trials and 170,000 participants. Testing the inflammation hypothesis properly required a drug that lowers inflammation without touching LDL, which is what the later canakinumab and colchicine trials attempted. JUPITER is strong evidence that treating this population works, and it is not evidence about which of the two mechanisms did the work.
Written into the record, not signed off as a reviewed claim
CORONA: no benefit in 5,011 patients with ischaemic systolic heart failure
In plain words
Five thousand older patients with heart failure from coronary disease took rosuvastatin or placebo for nearly three years. Cholesterol and the inflammation marker both fell substantially. Deaths and heart attacks did not.
What was measured
Composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke over a median 32.8 months
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
CORONA randomised 5,011 patients aged at least 60 with NYHA class II-IV ischaemic systolic heart failure to rosuvastatin 10 mg daily or placebo. LDL fell 45.0% and high-sensitivity C-reactive protein 37.1% against placebo, both p<0.001. Over a median 32.8 months the primary composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke occurred in 692 rosuvastatin patients against 732 on placebo: hazard ratio 0.92 (95% CI 0.83 to 1.02), p=0.12. Deaths were 728 against 759: 0.95 (0.86 to 1.05), p=0.31. There were no significant differences in the coronary outcome or in cardiovascular death. A prespecified secondary analysis found fewer cardiovascular hospitalisations on rosuvastatin (2,193 against 2,564, p<0.001). No excess of muscle-related events occurred.
Written into the record, not signed off as a reviewed claim
GISSI-HF: a hazard ratio of exactly 1.00 in 4,574 heart failure patients
In plain words
An Italian trial repeated the question in heart failure of any cause, over nearly four years. The number of deaths in the two arms was as close to identical as a trial can produce.
What was measured
Time to death, and time to death or cardiovascular admission, over a median 3.9 years
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
GISSI-HF randomised 4,574 patients aged 18 or older with chronic NYHA class II-IV heart failure of any cause and any ejection fraction, across 326 cardiology and 31 internal medicine centres in Italy, to rosuvastatin 10 mg daily (n=2,285) or placebo (n=2,289), followed for a median 3.9 years. Death from any cause occurred in 657 (29%) on rosuvastatin against 644 (28%) on placebo: adjusted hazard ratio 1.00 (95.5% CI 0.898 to 1.122), p=0.943. Death or admission for cardiovascular reasons occurred in 1,305 (57%) against 1,283 (56%): adjusted hazard ratio 1.01 (99% CI 0.908 to 1.112), p=0.903. Gastrointestinal disorders were the commonest adverse reaction and were less frequent on rosuvastatin than placebo.
Written into the record, not signed off as a reviewed claim
AURORA: LDL fell 43% on dialysis and nothing else moved
In plain words
In nearly three thousand people on haemodialysis, rosuvastatin lowered cholesterol substantially over almost four years and changed neither cardiovascular events nor deaths.
What was measured
Cardiovascular death, non-fatal myocardial infarction or non-fatal stroke over a median 3.8 years in haemodialysis
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
AURORA randomised 2,776 patients aged 50 to 80 on maintenance haemodialysis to rosuvastatin 10 mg daily or placebo. At 3 months mean LDL reduction was 43%, from a mean baseline of 100 mg/dL. Over a median 3.8 years, the combined primary endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke occurred in 396 rosuvastatin patients against 408 on placebo: 9.2 against 9.5 events per 100 patient-years, hazard ratio 0.96 (95% CI 0.84 to 1.11), p=0.59. Rosuvastatin had no effect on any individual component. All-cause mortality was 13.5 against 14.0 events per 100 patient-years: hazard ratio 0.96 (0.86 to 1.07), p=0.51.
Written into the record, not signed off as a reviewed claim
HOPE-3: it works in intermediate risk, and it produces measurable side effects
In plain words
A large, ethnically diverse trial in people at moderate risk without heart disease found a clear reduction in events. It also found more cataract surgery and more muscle symptoms than placebo.
What was measured
Two co-primary cardiovascular composites, plus cataract surgery and muscle symptoms, over a median 5.6 years
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
HOPE-3 randomised 12,705 participants in 21 countries without cardiovascular disease and at intermediate risk to rosuvastatin 10 mg daily or placebo, median follow-up 5.6 years. Mean LDL was 26.5% lower on rosuvastatin. The first co-primary outcome of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke occurred in 235 (3.7%) against 304 (4.8%): hazard ratio 0.76 (95% CI 0.64 to 0.91), p=0.002. The second co-primary outcome, adding revascularisation, heart failure and resuscitated arrest, occurred in 277 (4.4%) against 363 (5.7%): 0.75 (0.64 to 0.88), p<0.001. Results were consistent across baseline risk, lipid level, C-reactive protein, blood pressure and ethnic group. There was no excess of diabetes or cancer, but there was an excess of cataract surgery (3.8% against 3.1%, p=0.02) and of muscle symptoms (5.8% against 4.7%, p=0.005).
Written into the record, not signed off as a reviewed claim
Three failures in a row redrew the boundary of where statins work
In plain words
Two heart failure trials and one dialysis trial all showed large falls in cholesterol and no change in outcomes. The lesson taken from them is that a statin helps where atherosclerotic events drive the risk, and not where something else does.
What was measured
That statin benefit generalises to any population with high cardiovascular mortality or high inflammatory burden — three trials totalling 12,361 patients say it does not
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
CORONA, GISSI-HF and AURORA together randomised 12,361 patients, achieved LDL reductions of 45%, an unreported but comparable magnitude, and 43% respectively, and produced hazard ratios of 0.92 (p=0.12), 1.00 (p=0.943) and 0.96 (p=0.59) on their primary endpoints. All three enrolled populations with high total mortality driven substantially by pump failure, arrhythmia and non-atherosclerotic vascular disease rather than by plaque rupture. The consistent interpretation is that lowering LDL reduces atherothrombotic events and does not reduce deaths that were never going to be atherothrombotic — a boundary condition the earlier trials could not reveal because they enrolled people whose risk was atherosclerotic. It also weakens any general claim that statin benefit tracks inflammatory burden, since all three of these populations have high C-reactive protein.
This order is fixed in code and does not count clicks or time on the page.
What is not here
3 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
The older medicine-wide conclusion held in this record
Written for a clinical reader, and about the medicine as a whole rather than about one indication, population and set of trials. RNAWiki does not treat it as a programme conclusion and no reviewer has signed it off in that form. It is here word for word because it is what the record holds.
The most potent oral statin per milligram, with two positive primary-prevention outcome trials in 17,802 and 12,705 participants, and three consecutive negative outcome trials in 5,011 patients with ischaemic heart failure, 4,574 with heart failure of any cause, and 2,776 on haemodialysis — a pattern that constrains the inflammation hypothesis its most famous trial was designed to prove.
Recorded evidence blocks (14)
Q1
What did Rosuvastatin's largest trial (2133900 people) and its longest (14 years) measure?
2133900 people in Rosuvastatin's largest registered study, 14 years in its longest registered window, measuring All-cause mortality. ClinicalTrials.gov · 2026-09-01
222 phase1, 130 phase3, 119 phase4, 68 phase2, 34 na, 16 na or unstated, 9 early phase1; NCT07012629; 2040-01-01; no ageing endpoint recorded. Last human test completed 2026, NCT07717788.
Interpretation These counts include studies where Rosuvastatin was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase1
222
phase3
130
phase4
119
phase2
68
na
34
na or unstated
16
2 more recorded rows
early phase1
9
Last recorded human testNCT07717788
2026-07-01
recorded 2026-09-01 · last checked 2026-09-04
Q2
From mouse to human: where has Rosuvastatin shown lifespan?
20 recorded entries; human; also "warfarin plus ABT-335 plus rosuvastatin 5 mg", "warfarin plus ABT-335 plus rosuvastatin 20 mg", "Comparator: rosuvastatin 5 mg + ezetimibe 10 mg"
Show the evidence
human
NCT00240331
10mg Rosuvastatin
NCT00487136
warfarin plus ABT-335 plus rosuvastatin 5 mg
NCT00487136
warfarin plus ABT-335 plus rosuvastatin 20 mg
NCT00783263
Comparator: rosuvastatin 5 mg + ezetimibe 10 mg
NCT00783263
Comparator: rosuvastatin 10 mg
NCT00783263
Comparator: rosuvastatin 10 mg + ezetimibe 10 mg
14 more recorded rows
humanNCT00783263
Comparator: rosuvastatin 20 mg
humanNCT00997880
Rosuvastatin calcium 40mg
humanNCT00997880
CRESTOR® 40mg
humanNCT00997880
CRESTOR® 10mg
humanNCT01058915
Rosuvastatin 5mg
humanNCT01058915
Rosuvastatin 40mg
humanNCT01146483
Crestor 10 mg
humanNCT01218802
Rosuvastatin 10 mg. daily for 96 weeks
humanNCT01223625
Rosuvastatin 5mg/day
humanNCT01223625
Rosuvastatin 40mg/day
humanNCT01228227
ROSUVASTATIN 40 mg
humanNCT01364220
Crestor 20mg
humanNCT01411111
Rosuvastatin 10 mg
humanNCT01425398
Rosuvastatin 40 mg/day
recorded 2026-09-01 · last checked 2026-09-04
Q5
Rosuvastatin's half-life is approximately 19 hours — which schedules were studied?
approximately 19 hours, the half-life Rosuvastatin's label states. openfda-label · 6ef51f7c-2899-4b09-bf8b-09e5b4ac3424 · 2026-08-27
bioavailability approximately 20% %.
Show the evidence
half life
approximately 19 hours hours; The elimination half-life of rosuvastatin is approximately 19 hours.
bioavailability
approximately 20% %; The absolute bioavailability of rosuvastatin is approximately 20%.
metabolism
Elimination Metabolism Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite.
recorded 2026-08-27 · last checked 2026-09-04
Q6
Could one person measure Rosuvastatin's effect on ldl c from baseline to week 12?
Ldl c from baseline to week 12: measured in Rosuvastatin's trials.
ldl c from baseline to week 12 is the recorded endpoint.
Show the evidence
biomarkers
ldl c from baseline to week 12; 2026-09-01
reduction of ldl c following 12 weeks of treatment; 2026-09-01
time to major cardiac event; 2026-09-01
low density lipoprotein cholesterol; 2026-09-01
fasting plasma low density lipoprotein cholesterol; 2026-09-01
lipopolysaccharide binding protein; 2026-09-01
14 more recorded rows
biomarkers
urinary protein/creatinine in type 1 or 2 diabetes; 2026-09-01
biomarkers
changes in apob/apoa i levels; 2026-09-01
biomarkers
urinary protein/creatinine at week 52; 2026-09-01
biomarkers
triglycerides from baseline to final visit; 2026-09-01
biomarkers
reduction in ldl c after 6 weeks; 2026-09-01
biomarkers
all cause mortality; 2026-09-01
biomarkers
nihss; 2026-09-01
biomarkers
endothelial activation markers; 2026-09-01
biomarkers
apolipoprotein at week 6; 2026-09-01
biomarkers
achieving a target of fasting ldl c of 2mmol/ at study end; 2026-09-01
low density lipoprotein cholesterol level after 8 weeks; 2026-09-01
biomarkers
total cholesterol ldl c hdl c and triglycerides; 2026-09-01
biomarkers
ldl c level from baseline to the study endpoint; 2026-09-01
half life
2026-09-04; halfLife; hours; approximately 19 hours; 2026-08-27
human trials at or under30
151
smallest human trial
0; NCT00371579; NA; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; WITHDRAWN
Q7
Which of achieving a target of fasting ldl c of 2mmol/ at study end, adverse event and safety laboratory assessments and all cause mortality did Rosuvastatin's trials measure?
achieving a target of fasting ldl c of 2mmol/ at study end, adverse event and safety laboratory assessments and all cause mortality lead 40 outcome terms across Rosuvastatin's trials. ClinicalTrials.gov · 2026-09-01
low density lipoprotein cholesterol, fasting plasma low density lipoprotein cholesterol, lipopolysaccharide binding protein, urinary protein/creatinine in type 1 or 2 diabetes, changes in apob/apoa i levels and urinary protein/creatinine at week 52 follow.
Show the evidence
ldl c from baseline to week 12
1
reduction of ldl c following 12 weeks of treatment
1
time to major cardiac event
1
low density lipoprotein cholesterol
1
fasting plasma low density lipoprotein cholesterol
1
lipopolysaccharide binding protein
1
14 more recorded rows
urinary protein/creatinine in type 1 or 2 diabetes
1
changes in apob/apoa i levels
1
urinary protein/creatinine at week 52
1
triglycerides from baseline to final visit
1
reduction in ldl c after 6 weeks
1
all cause mortality
1
nihss
1
endothelial activation markers
1
apolipoprotein at week 6
1
achieving a target of fasting ldl c of 2mmol/ at study end
"A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer"; n 23; "Maximum Observed Plasma Concentration (Cmax)"; 2027-12-31
NCT03016819
"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)"; n 325; "Objective Response Rate (ORR) (ASPS)"; 2028-12
NCT03169985
"Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque"; n 280; "Change in percent atheroma volume(PAV) in non-culprit lesions"; 2027-01-28
NCT03511118
"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants"; n 1600; "M/P ratio"; 2028-07-31
NCT04319627
"Statins for Venous Event Reduction in Patients With Venous Thromboembolism"; n 2700; "Recurrent Major VTE"; 2028-04
NCT04499859
"Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI"; n 3548; "Major Adverse Cardiovascular Events (MACE)"; 2027-08-30
14 further recorded trials
NCT04602754
"Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia."; n 228; "Reduction of glycated hemoglobin levels measured between the first visit and the last visit."; 2027-09
NCT04699279
"Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)"; n 300; "Aortic adverse events"; 2024-12-31
NCT04847752
"Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis"; n 1000; "all-cause mortality"; 2028-12-31
NCT04903223
"Liver Adiposity Effects on Pediatric Statin"; n 50; "Evaluate effect of Liver Fat Percentage (on MRI) on AUC"; 2027-03-31
NCT05483010
"Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)"; n 16; "Change in hs-CTRP levels in peripheral blood during statin therapy"; 2028-05-31
NCT05614739
"FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3"; n 677; "Overall Response Rate (ORR)"; 2027-06
NCT05832229
"Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States"; n 256; "Mean change in liver stiffness"; 2029-08-31
NCT05850091
"Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine"; n 200; "Change in total non-calcified plaque volume from baseline to one year"; 2027-06-01
NCT05912387
"Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study"; n 15; "Change in bile acid (BA) profile: total bile acid"; 2027-12-31
NCT06338293
"Effects of Inclisiran Combined With Statins on the Morphology of Coronary Vulnerable Plaques"; n 40; "The change rate of the thinnest fibrous cap of vulnerable plaque at the target vascular lesion from baseline to one-year follow-up(△ FCT%)"; 2025-12-31
NCT06358313
"Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Small Vessel Stroke"; n 600; "the rate of new stroke at 90 days"; 2026-05-30
NCT06360120
"Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke"; n 600; "the rate of new stroke at 90 days"; 2025-10-01
NCT06488105
"Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial"; n 130; "Percent change in low-density lipoprotein cholesterol (LDL-C) at 30 days"; 2029-03-31
NCT06538649
"Effect of Statins on Crohn's Disease"; n 20; "Rutgeerts score"; 2028-10-31
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which running trial of Rosuvastatin could settle vo2max?
NCT07401017 measures VO₂max (mL/kg/min), reading out 2026-10-31.
2 open trials; n 40; "The Effects of Rosuvastatin on Running Training Adaptation and Safety"
Show the evidence
Trial
NCT07401017
"The Effects of Rosuvastatin on Running Training Adaptation and Safety"; n 40; "VO₂max (mL/kg/min)"; 2026-10-31
NCT04847752
"Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis"; n 1000; "all-cause mortality"; 2028-12-31
Q10
Which 287 trials of Rosuvastatin posted no result?
Posted no result
287 of 287 completed trials
Registrations
NCT00657527, NCT00651144, NCT00379249, NCT00653744, NCT00654446 and NCT00329173, and 281 more
Completion dates
oldest 2002-12; newest 2024-08-31
Show the evidence
Trial
NCT00657527
2002-12
NCT00651144
2003-05
NCT00379249
2004-02
NCT00653744
2004-03
NCT00654446
2004-04
NCT00329173
2004-08
14 further recorded trials
NCT00654394
2004-08
NCT00653588
2004-09
NCT00654173
2004-09
NCT00654407
2004-09
NCT00654537
2004-10
NCT00654602
2004-11
NCT00240266
2004-12
NCT00239330
2005-02
NCT00653965
2005-02
NCT00654303
2005-02
NCT00654485
2005-02
NCT00654225
2005-03
NCT00660764
2005-04
NCT00079638
2005-05
Q11
At the median, Rosuvastatin's trials enrolled 64 people — anything larger?
Median enrolment
64
Largest enrolment
2133900
Registered trials counted
576
Q12
What do 27595 spontaneous reports say about Rosuvastatin — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Rosuvastatin appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 27595 reaction mentions were counted: myalgia 6976; rhabdomyolysis 6575; drug interaction 3621; blood creatine phosphokinase increased 3155. open-targets-adr · CHEMBL1496 · 2026-06-24
Show the evidence
myalgia
6976
rhabdomyolysis
6575
drug interaction
3621
blood creatine phosphokinase increased
3155
muscular weakness
2041
myopathy
1546
4 more recorded rows
renal failure acute
1476
liver function test abnormal
997
myositis
734
immune-mediated myositis
474
recorded 2026-06-24 · last checked 2026-09-04
Q13
Was Rosuvastatin studied with fasting and exercise?
fasting and exercise are named in Rosuvastatin's label sentences: "This open-label, 3 × 3 crossover clinical trial evaluated the pharmacokinetics and safety of a fixed-dose combination (FDC) of cilostazol/rosuvastatin (200 + 20 mg) versus a concurrent administration of the separate components (SCs) under both fasted and fed conditions." openfda-label+europepmc · 2026-08-30
2 recorded statements; fasting, exercise
Show the evidence
fasting
This open-label, 3 × 3 crossover clinical trial evaluated the pharmacokinetics and safety of a fixed-dose combination (FDC) of cilostazol/rosuvastatin (200 + 20 mg) versus a concurrent administration of the separate components (SCs) under both fasted and fed conditions.
exercise
Participants with NAFLD/NASH were randomized into 4 groups (n=151 each): diet-exercise, atorvastatin, rosuvastatin, or pitavastatin for 1 year (i.e., until the next routine evaluation).
recorded 2026-08-30 · last checked 2026-09-04
Q14
What is recorded about Rosuvastatin and AMPK?
"However, the administration of rosuvastatin increased the ratio of phosphorylated AMPK to total AMPKα, thus inhibiting the formation of new blood vessels, as indicated by CD31-positive staining mainly in the sub-epithelial region." — where Rosuvastatin and AMPK appear together. Europe PMC · pathway abstract search · 2024-07-29
"However, the administration of rosuvastatin increased the ratio of phosphorylated AMPK to total AMPKα, thus inhibiting the formation of new blood vessels, as indicated by CD31-positive staining mainly in the sub-epithelial region."
mTORPMID 38365767
"Sirolimus and rosuvastatin inhibited pro-inflammatory cytokine production during the acute stage and regulated Akt/mTOR/NF-κB/STAT3 signaling in the chronic stage of NIH progression."
autophagyPMID 39125836
"Since autophagy is involved in inflammatory mechanisms, we investigated the actions of pro-inflammatory lipopolysaccharide (LPS) and anti-inflammatory rosuvastatin (RST) in secondary microglial cultures with or without bafilomycin A1 (BAF) pretreatment, an antibiotic that potently inhibits autophagosome fusion with lysosomes."
mTOR
"Conclusions Sirolimus and rosuvastatin inhibited pro-inflammatory cytokine production during the acute stage and regulated Akt/mTOR/NF-κB/STAT3 signaling in the chronic stage of NIH progression."
sirtuin
PMID 35988282
"The study aimed to observe the effect of rosuvastatin on myocardial apoptosis in hypertensive rats through the silent information regulator 1 (SIRT1)/nuclear factor-κB (NF-κB) signaling pathway."
PMID 35988282
"Rosuvastatin can inhibit myocardial apoptosis in hypertensive rats through up-regulating SIRT1 and down-regulating NF-κB."
autophagy
PMID 33846234
"The ability of rosuvastatin to inhibit apoptosis and p38 phosphorylation was suppressed by treatment with 3-methyladenine (an autophagy inhibitor) but promoted by rapamycin (an autophagy activator) treatment."
PMID 33846234
"In conclusion, our observations suggest that rosuvastatin inhibits p38 phosphorylation through autophagy and subsequently reduces intracellular ROS levels, leading to its vasoprotective activity."
sirtuinPMID 36582738
"The bibliometric analysis of co-occurrence keywords showed that inflammation in DCM is composed of numerous molecules (NF-κB, NLRP3 inflammasome, Nrf-2, TNF-α, protein kinase C, PPARα, TLR4, p38 mitogen-activated protein kinase, TGF-β, Sirt1, and AKT), a variety of cardiac cell types (stem cell, fibroblast, and cardiomyocyte), physiological processes (apoptosis, oxidative stress, autophagy,…"
mTORPMID 30481906
"<b>Objective:</b> To investigate the effects of rosuvastatin (RSV)on autophagy and apoptosis of myocardial cells in rats with acute myocardial infarction. <b>Methods:</b> SD rats were divided into control (Sham group), acute myocardial infarction model rats (AMI group), AMI rats treated by RSV with the dose of 5 mg·kg(-1)·d(-1) (RSV group), AMI rats treated by RSV and AMPK inhibitor Compound C at…"
AMPK
PMID 30481906
"<b>Objective:</b> To investigate the effects of rosuvastatin (RSV)on autophagy and apoptosis of myocardial cells in rats with acute myocardial infarction. <b>Methods:</b> SD rats were divided into control (Sham group), acute myocardial infarction model rats (AMI group), AMI rats treated by RSV with the dose of 5 mg·kg(-1)·d(-1) (RSV group), AMI rats treated by RSV and AMPK inhibitor Compound C at…"
PMID 29494287
"Overall, we show that the resveratrol decreased BP better than Crestor, abolished ROS generation, and enhanced the ERK1/2-RSK-nNOS pathway by activating AMPK to downregulate Rac1-induced NADPH oxidase levels in the NTS during oxidative stress-associated hypertension."
NAD+
PMID 22817606
"After rosuvastatin, relaxations to ACh were normalized, fully sensitive to L-NAME, and no longer affected by SC-560, SQ-29548 or NAD(P)H oxidase inhibitors."
PMID 22817606
"Angiotensin II increased phosphorylation of NAD(P)H oxidase subunit p47phox and its binding to subunit p67phox, effects inhibited by rosuvastatin."
PMID 27225894
"Treatment with a noneffective dose of rosuvastatin (0.5 mg kg(-1) day(-1)) plus a low dose of C21 (1 μg kg(-1) day(-1)) inhibited the PCNA labeling index, superoxide anion production, mRNA expressions of NAD(P)H subunits, and mRNA and protein expressions of inflammatory markers associated with marked inhibition of neointima formation."
recorded 2024-07-29 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 11 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.